Abstract
Systemic sclerosis is a chronic autoimmune condition with a complex pathogenesis and a high rate of mortality and morbidity. Internal organ involvement requires interdisciplinary approach in individual patient management. New discoveries in the pathogenesis of scleroderma herald a drastic change in the traditional outlook to therapy and have led to the development of the target-based approach in management. The challenge at present is to translate these advances in molecular mechanisms into well-designed clinical trials that will recognize potential disease-modifying therapies. This article is an evidence-based review of prevailing treatment options and future therapeutic targets in systemic sclerosis.
Similar content being viewed by others
Abbreviations
- SSc:
-
Systemic sclerosis
- OS:
-
Oxidative stress
- lcSSc:
-
Limited cutaneous SSc
- dcSSc:
-
Diffuse cutaneous SSc
- TGF-ß:
-
Transforming growth factor-ß
- CCB:
-
Calcium channel blocker
- RCT:
-
Randomized, controlled trial
- DHP:
-
Dihydropyridines
- ACE:
-
Angiotensin-converting enzyme
- VCAM-1:
-
Vascular cell adhesion molecule 1
- ICAM-1:
-
Intercellular adhesion molecule 1
- ET-1:
-
Endothelin 1
- PINP:
-
Procollagen type I N-terminal propeptide
- ARB:
-
Angiotensin receptor blocker
- PAH:
-
Pulmonary hypertension
- SMW distance:
-
6-min walk distance
- VAS:
-
Visual analog scale
- DU:
-
Digital ulcer
- PDE5:
-
Phosphodiesterase
- RCS:
-
Raynaud’s condition score
- 5 HT:
-
5 hydroxytryptamine [serotonin]
- IL-1:
-
Interleukin 1
- TNF-α:
-
Tumor necrosis factor α
- MTX:
-
Methotrexate
- TSS:
-
Total skin score
- ILD:
-
Interstitial lung disease
- MMF:
-
Mycophenolate mofetil
- IVIG:
-
Intravenous immunoglobulin
- HSCT:
-
Hematopoietic stem cell transplantation
- TGF β:
-
Transforming growth factor β
- PDGF:
-
Platelet-derived growth factor
- Rock:
-
Rho kinase
- ECM:
-
Extracellular matrix
- (PPAR)-γ:
-
Peroxisome proliferator-activated receptor
- ROS:
-
Reactive oxygen species
References
Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78–85
Tikly M, Channa K, Theodorou P et al (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25:320–324
Herrick AL, Rieley F, Schofield D et al (1992) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483
Veale DJ, Collidge TA, Belch J (1995) Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54:853–855
Ho M, Veale DJ, Eastmond C et al (2000) Macrovascular disease in systemic sclerosis. Ann Rheum Dis 59:39–43
Shoenfeld Y, Gerli R, Doria A et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347
Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:1–8
LeRoy CE (1996) Systemic sclerosis: a vascular perspective. Rheum Dis Clin N Am 22:675
Matucci Cerinic M, Fiori G, Grenbaum E et al (2003) Macrovascular disease in systemic sclerosis. In: Furst D, Clements P (eds) Systemic sclerosis. Lippincott Williams and Wilkins, Baltimore
Shand L, Lunt M, Nihtyanova S et al (2007) Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 56:2422–2431
Kowal-Bielecka O, Landewe′ R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620–628
Kawakami T, Ihn H, Xu W et al (1998) Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 110(1):47–51
Leask A (2006) Scar wars: is TGFbeta the phantom menace in scleroderma? Arthritis Res Ther 8(4):213
Wei, Jun, Leng et al (2009) Profibrotic Wnt signaling in human mesenchymal cells: implications for scleroderma. Arthritis Rheumatism, vol 60, Abstract Supplement
Julie B, Jennifer F, Kimberly J et al (2008) Increased expression of Wnt2 and SFRP4 in Tsk Mouse Skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Investigat Dermatol 128:871–881
Ayumi Y, Yohei I, Kazuhiro K et al (2008) CD19 Regulates skin and lung fibrosis via toll-like receptor signaling in a model of Bleomycin-induced scleroderma. Am J Pathol 172(6):1650–1663
Fineschi S, Goffin L, Rezzonico R et al (2008) Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 58(12):3913–3923
Agarwal SK, Wu M, Livingston CK (2011) Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Therapy 13:R3
Silverstein JL, Steen VD, Medsger TA et al (1988) Cutaneous hypoxia in patients with systemic sclerosis (Scleroderma). Arch Dermatol 124(9):1379–1382
Hong K-H, Yoo S-A, Kang S–S et al (2006) Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol 146(2):362–370
Schild C, Trueb B (2002) Mechanical stress is required for high-level expression of connective tissue growth factor. Exp Cell Res 274(1):83–91
Wei J, Bhattacharyya S, Tourtellotte WG, Varga J (2010) Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 10(5):267–275
Flavahan NA, Flavahan S, Mitra S, Chotani MA (2003) The vasculopathy of Raynaud’s phenomenon and scleroderma. Rheum Dis Clin North Am 29:275–291
Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM (1999) Activation of microvascular pericytes in autoimmune Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 42:930–941
Prescott RJ, Freemont AJ, Jones CJP et al (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263
Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847
Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111
Wollersheim H, Thien T (1991) Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud’s phenomenon. J Cardiovasc Pharmacol 18:813–818
Schmidt JF, Valentin N, Neilsen SL (1989) The clinical effect of felodipine and nifedipine in Raynaud’s phenomenon. Eur J Clin Pharmacol 37:191–192
La Civita L, Pitaro N, Rossi M et al (1997) Amlodipine in the treatment of Raynaud’s phenomenon. A double-blind placebo-controlled crossover study. Clin Drug Invest 13:126–131
Kahan A, Amor B, Menkes CJ (1985) A randomised double-blind trial of diltiazem in the treatment of Raynaud’s phenomenon. Ann Rheumat Dis 44:30–33
Da costa J, Gomesja, Espirito Santo J et al (1987) Inefficacy of diltiazem in the treatment of Raynaud’s phenomenon with associated connective tissue disease: a double blind placebo controlled study. J Rheumatol 14:858–859
Kinney EL, Nicholas GG, Gallo J (1982) The treatment of severe Raynaud’s phenomenon with verapamil. J Clin Pharmacol 22(1):74–76
Allanore Y, Borderie D, Lemaréchal H, Ekindjian OG, Kahan A (2004) Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther 6:R309–R314
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev (2):CD000953
Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M et al (1998) Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41:670–677
Black CM, Halkier SA, Rensen L, Belch JJ, Ullman S, Madhok R et al (1998) Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 37:952–960
Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG et al (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298:561–564
Scorza R, Caronni M, Mascagni B et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503–508
Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP (1992) Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19:1407–1414
Hunzelmann N, Scleroderma TK (2010) From pathophysiology to novel therapeutic approaches. Exp Dermatol 19:393–400
Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM et al (2000) Inhaled Iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH study group. Ann Intern Med 132:435–443
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann Intern Med 132:425–434
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve′ P et al (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40:780–788
McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477–1482
Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ et al (2004) Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126:420–427
Vayssairat M (1996) Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud’s phenomenon. J Rheumatol 23:1917–1920
Vayssairat M (1999) Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 26(10):2173–2178
Galie` N, Humbert M, Vachie′ry J-L et al (2002) Effects of Beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502
Gliddon AE, Doré CJ, Black CM (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56(11):3837–3846
Dziadzio M, Denton CP, Smith R et al (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42(12):2646–2655
Yatsyshyn N, Yatsyshyn R, Neyko YE (2010) Telmisartan improves endothelial function in scleroderma patients with pulmonary hypertension. J Hypertens 28:e550
Pope J, Fenlon D, Thompson A et al (2000) Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000956
Chung L, Shapiro L, Fiorentino D et al (2009) MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon. Random Control Trial Arthritis Rheumatism 60(3):870–877
Badesch DB, Hill NS, Burgess G et al (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417–2422
Xiong C-M, Lu X-L, Shan G-L et al (2011) Oral Sildenafil therapy for chinese patients with pulmonary arterial hypertension: a multicenter study. J Clin Pharm, PMID 21415281
Lee AJ, Chiao TB, Tsang MP (2005) Sildenafil for pulmonary hypertension. Ann Pharmacother 39(5):869–884
Herrick AL, van den Hoogen F, Gabrielli A et al (2011) Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheumatism 63(3):775–782
Brueckner CS, Becker MO, Kroencke T (2010) Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 69:1475–1478
Yung A, Reay N, Goodfield MD (2005) Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate in limited systemic sclerosis. Arch Dermatol 141:831–883
Shenoy P, Agarwal V, Kumar S et al (2008) Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial [abstract]. Arthritis Rheum 58(9 Suppl):S402
Galiè N, Brundage BH, Ghofrani HA et al (2009) Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894–2903 [PubMed]
Ghofrani HA, Voswinckel R, Reichenberger F et al (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44:1488–1496
Toque HA, Teixeira CE, Priviero FB (2008) Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 154(4):787–796
Caglayan E, Huntgeburth M, Karasch T (2006) Phosphodiesterase Type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 166:231–233
Rajagopalan S, Pfenninger D, Somers E et al (2003) Effects of cilostazol in patients with Raynaud’s syndrome. Am J Cardiol 92(11):1310–1315
Korn JH, Mayes M, Matucci CM, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993
Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70(1):32–38
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903
Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A et al (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24:353–359
King Jr. TE, Behr J, Brown KK et al (2008) BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respirat Crit Care Med 177:75–81
King Jr. TE, Brown KK, Raghu G (2011) BUILD-3: a randomized, controlled trial of Bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (Published ahead of print on April 7, 2011)
Silver RM (2008) Endothelin and scleroderma lung disease. Rheumatology 47:v25–v26
Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S et al (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441–447
Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S et al (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47:2049–2056
Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA et al (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117:3010–3019
Eddahibi S, Guignabert C, Barlier-Mur AM et al (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113:1857–1864
Coleiro B, Marshall SE, Denton CP et al (2001) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitr fluoxetine. Rheumatology (Oxford) 40:1038–1043
Marcos E, Adnot S, Pham MH et al (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168:487–493
Kawut SM, Horn EM, Berekashvili KK et al (2006) Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 19:370–374
Sambo P, Amico D, Giacomelli R et al (2001) Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 28:2257–2262
Nevskaya T, Ananieva L, Bykovskaia S et al. Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rheumatology 48(1):61–64
Quillinan NP, Denton CP (2009) Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 21:636–641
Das SN, Alam MR, Islam N et al (2005) Placebo controlled trial of methotrexate in systemic sclerosis. Mymensingh Med J: MMJ 14:71–74
van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35:364–372
Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351–1358
Hennessa S, Wigley FM (2007) Current drug therapy for scleroderma and secondary Raynaud’s phenomenon: evidence-based review. Curr Opin Rheumatol 19:611–618
Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666
Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter prospective, randomised, double-blind, placebo controlled trial of corticosteroids and intravenous cyclophosphamide, followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970
Tashkin DP, Elashoff R, Clements PJ et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026–1034
Berezne A, Ranque B, Valeyre D et al (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35:1064–1072
Nihtyanova SI, Brough GM, Black CM et al (2007) Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology 46:442–445
Swigris JJ, Olson AL, Fischer A et al (2006) Mycophenolate mofetil is safe, well tolerated and preserves lung function in patients with connective tissue disease related interstitial lung disease. Chest 130:30–36
Clements PJ, Lachenbruch PA, Sterz M et al (1993) Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36(1):75–83
Filaci G, Cutolo M, Basso M et al (2001) Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 40:1431–1432
Zachariae H, Halkier-Sorensen L, Heickendorff L, Zachariae E, Hansen HE (1990) Cyclosporin A treatment of systemic sclerosis. Br J Dermatol 122:677–681
Shegogue D, Trojanowska M (2004) Mammalian target of rapamycin positively regulates collagen Type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 279:23166–23175
Karleen Su T-I, Khanna D, Furst DE et al (2009) Rapamycin (rapa) vs methotrexate (mtx) in early diffuse systemic sclerosis (ssc): a 48-week randomized, single-blind pilot safety study. Arthritis Rheum 60(12):3821–3830
Asano N, Fujimoto M, Yazawa N et al (2004) B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 165:641–650
Saito E, Fujimoto M, Hasegawa M et al (2002) CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109:1453–1462
Hasegawa M, Hamaguchi Y, Yanaba K et al (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954–966
Yoshizaki A, Iwata Y, Komura K et al (2008) CD19 regulates and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 172:1650–1663
Bosello S, De Santis M, Lama G et al (2010) B cell depletion in diff use progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow up open-label trial. Arthritis Res Ther 12:R54
Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel P, Simms RW (2009) B cell depletion with rituximab in patients with diff use cutaneous systemic sclerosis. Arthritis Rheum 60:578–583
Smith V, Van Praet JT, Vandooren B et al (2010) Rituximab in diff use cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193–197
Daoussis D, Liossis SC, Tsamandas AC et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49:271–280
Sato S, Hasegawa M, Takehara K (2001) Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27:140–146
Koch AE, Kronfeld-Harrington LB, Szekanecz et al (1993) In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 61:239–246
Shima Y, Kuwahara Y, Murota H et al (2010) The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 49:2408–2412
Distler JHW, Schett G, Gay S, Distler O (2008) The controversial role of tumour necrosis factor a in fibrotic diseases. Arth Rheum 58:2228–2235
Lam GK, Hummers LK, Woods A et al (2007) Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 34:1636–1637
Denton CP, Engelhart M, Tvede N et al (2008) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 68(9):1433–1439
Phumethum V, Jamal S, Johnson SR (2011) Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 38(2):289–296
Levy Y, Sherer Y, Langevitz P et al (2000) Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin: a preliminary report. Clin Rheumatol 19:207–211
Levy Y, Amital H, Langevitz P et al (2004) Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 50:1005–1007
Nacci F, Righi A, Conforti ML et al (2007) Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 66:977–979
Ihn H, Mimura Y, Yazawa N et al (2007) High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 156:1058–1060
Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O (2002) The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 46:1689–1690
Amital H, Rewald E, Levy Y et al (2003) Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 62:175–177
Postlethwaite AE, Wong WK, Clements P et al (2008) A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 58:1810–1822
Ghosh AK, Yuan W, Mori Y, Chen S, Varga J (2001) Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 276:11041–11048
Varga J, Olsen A, Herhal J, Constantine G, Rosenbloom J, Jimenez SA (1990) Interferon-gamma reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-beta in normal human fibroblasts. Eur J Clin Invest 20:487–493
Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G et al (2006) Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 146:371–380
Vonk MC, Marjanovic Z, van den Hoogen FHJ et al (2008) Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67:98–104
Nash RA, McSweeney PA, Corfford LJ et al (2007) High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110:1388–1396
Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F et al (1999) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42:1194–1203
Derk CT, Huaman G, Jimenez SA (2008) A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol 158(5):1063–1068
Grassegger A, Schuler G, Hessenberger G et al (1998) Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 139:639–648
Black CM, Silman AJ, Herrick AI et al (1999) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42:299–305
Kreuter A, Breuckmann F, Uhle A et al (2004) Low dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 50(5):740–747
Kanekura T, Fukumaru S, Matsushita S et al (1996) Successful treatment of scleroderma with PUVA therapy. J Dermatol 23:455–459
Hofer A, Soyer HP (1999) Oral psoralen-UV-A for systemic scleroderma. Arch Dermatol 135:603–604
Pasic A, Ceovic R, Lipozencic J et al (2003) Phototherapy in pediatric patients. Pediatr Dermatol 20(1):71–77
Knobler RM, French LE, Kim Y, Bisaccia E, Graninger W (2006) A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 54(5):793–799
Sunderkotter C, Kuhn A, Hunzelmann N, Beissert S (2006) Phototherapy: a promising treatment option for skin sclerosis in scleroderma? Rheumatology 45:iii52–iii54
Unemori EN, Amento EP (1990) Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 265:10681–10685
Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD et al (2000) Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo controlled trial. Ann Intern Med 132:871–879
Nagler A, Miao HQ, Aingorn H et al (1997) Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler Thromb Vasc Biol 17:194–202
Pines M, Snyder D, Yarkoni S, Nagler A (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9:417–425
Salikhov IG, Bodrova RA, Ziganshina LE (2002) Ximedon-electrophoresis in rehabilitation of patients with systemic scleroderma. Vopr Kurortol Fizioter Lech Fiz Kult 5:33–36
Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T (2002) Open-label compassionate use one year treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41:1118–1123
Taniguchi H, Ebina M, Kondoh Y, Ogura T et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. ERJ 35(4):821–829
Simone NL, Soule BP, Gerber L, Augustine E, Smith S, Altemus RM, Mitchell JB, Camphausen KA (2007) Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiat Oncol 2:19
Alarcon-Segovia D, Ramos-Niembro F, Ibanez de Kasep G (1979) Long-term evaluation of colchicine in the treatment of scleroderma. J Rheumatol 6(6):705–712
Guttadauria M, Diamond H, Kaplan D (1977) Colchicine in the treatment of scleroderma. J Rheumatol 4(3):272–276
Le CH, Morales A, Trentham DEK (1998) Minocycline in early diffuse scleroderma. Lancet 352:1755–1756
Mayes MD, O’Donnell D, Rothfield NF, Csuka ME (2004) Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 50(2):553–557
Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816–827
Trojanowska M, Varga J (2007) Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol 19:568–573
Ihn H, Yamane K, Kubo M, Tamaki K (2001) Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 44:474–480
Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M (1998) Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 110:47–51
McCormick LauraL, Zhang Yan et al (1999) Anti-TGF-ß treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163:5693–5699
Denton CP, Merkel PA, Furst DE (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56(1):323–333
Kubo M, Czuwara-Ladykowska J, Moussa O et al (2003) Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 163:571–581
Asano Y, Stawski L (2010) Faye Hant Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 176(4):1983–1998
Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M (2001) Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 276:20839–20848
Schermuly RT, Dony E, Ghofrani HA et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811–2821
Ghofrani HA, Seeger W, Grimminger F (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 29:353
Bailey SR, Eid AH, Mitra S, Flavahan S et al (2004) Rho kinase mediates cold-induced constriction of Cutaneous Arteries role of α2C-adrenoceptor translocation Circul Res 94:1367
Dees C, Pileckyte M et al (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheumatism 58(8):2553–2564
Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G (1998) Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 9:1377–1388
Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol 35(9):1801–1808
Wei J, Bhattacharyya S, Varga J (2010) Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol 22(6):671–676
Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J (2004) Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50:1305–1318
Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y et al (2009) Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 23(9):2968–2977
Shi-wen X, Eastwood M, Stratton RJ et al (2010) Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology 49:259–263
Sambo P, Baroni SS, Luchetti M et al (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44(11):2653–2664
Denton CP, Bunce TD, Dorado MB et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology (Oxford) 38(4):309–315
Herrick AL, Hollis S, Schofield D et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18(3):349–356
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Topal, A.A., Dhurat, R.S. Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int 33, 1–18 (2013). https://doi.org/10.1007/s00296-012-2486-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-012-2486-1